Vedolizumab is used for the treatment of adult patients with moderately to severely active ulcerative colitis and Crohn’s disease who have had an inadequate response, loss of response, or intolerance to TNF-a inhibitors or immunomodulators, or who have had an inadequate response or intolerance to, or have developed dependence on corticosteroids [56]. This evidence concerns the gene TNF and ulcerative colitis.